These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 12189303)

  • 1. Dopamine and congestive heart failure: pharmacology, clinical use, and precautions.
    Van De Borne P; Somers VK
    Congest Heart Fail; 1999; 5(5):216-221. PubMed ID: 12189303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of dopamine in congestive heart failure: a contemporary appraisal.
    Varriale P
    Congest Heart Fail; 1999; 5(3):120-124. PubMed ID: 12189316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action.
    Elkayam U; Ng TM; Hatamizadeh P; Janmohamed M; Mehra A
    Circulation; 2008 Jan; 117(2):200-205. PubMed ID: 18172028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of systemic and renal effects of dopexamine and dopamine in norepinephrine-treated septic shock.
    Schmoelz M; Schelling G; Dunker M; Irlbeck M
    J Cardiothorac Vasc Anesth; 2006 Apr; 20(2):173-8. PubMed ID: 16616656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes.
    Valverde E; Pellicer A; Madero R; Elorza D; Quero J; Cabañas F
    Pediatrics; 2006 Jun; 117(6):e1213-22. PubMed ID: 16717120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
    Mahesh B; Yim B; Robson D; Pillai R; Ratnatunga C; Pigott D
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):370-6. PubMed ID: 18243724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.
    Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T
    Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of low-dose dopamine on ventilation in patients with chronic obstructive pulmonary disease.
    Ciarka A; Rimacchi R; Vincent JL; Velez-Roa S; Dumonceaux M; Leeman M; van de Borne P
    Eur J Clin Invest; 2004 Jul; 34(7):508-12. PubMed ID: 15255788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
    Behling A; Rohde LE; Colombo FC; Goldraich LA; Stein R; Clausell N
    J Card Fail; 2008 Apr; 14(3):189-97. PubMed ID: 18381181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal dose dopamine--it's myth and the truth.
    Padmanabhan R
    J Assoc Physicians India; 2002 Apr; 50():571-5. PubMed ID: 12164413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
    Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
    J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent potentiating diuretic effects of prednisone in congestive heart failure.
    Liu C; Chen H; Zhou C; Ji Z; Liu G; Gao Y; Tian L; Yao L; Zheng Y; Zhao Q; Liu K
    J Cardiovasc Pharmacol; 2006 Oct; 48(4):173-6. PubMed ID: 17086096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.
    Anwaruddin S; Lloyd-Jones DM; Baggish A; Chen A; Krauser D; Tung R; Chae C; Januzzi JL
    J Am Coll Cardiol; 2006 Jan; 47(1):91-7. PubMed ID: 16386670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal-dose dopamine: from hypothesis to paradigm to dogma to myth and, finally, superstition?
    Jones D; Bellomo R
    J Intensive Care Med; 2005; 20(4):199-211. PubMed ID: 16061903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
    Udelson JE; Orlandi C; Ouyang J; Krasa H; Zimmer CA; Frivold G; Haught WH; Meymandi S; Macarie C; Raef D; Wedge P; Konstam MA; Gheorghiade M
    J Am Coll Cardiol; 2008 Nov; 52(19):1540-5. PubMed ID: 19007589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.